Page 44 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 26, 2021   NEWTON, Mass., April 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Company's Type II Variation Marketing Authorization Application (MAA), which seeks to expand the currently authorized indication for NEXPOVIO® in the European Union to include, in combination with Velcade® (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at...

Senior honors defenses mark end of intensive research projects Share on: Posted on Wednesday, April 7, 2021 This spring, several Westminster College senior honors scholars will publicly defend their capstone research—a culmination of nearly two years’ worth of high-level academic exploration. “While every student at Westminster experiences capstone, students in the All-College Honors Program begin working on their capstone research early in the junior year, developing and proposing a project to their honors board of three faculty,” said Dr. Kristianne Kalata, director...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) News provided by Share this article Share this article NEWTON, Mass., March 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 93,600 shares of Karyopharm's common stock to 11 newly-hired employees, with a grant date of February 26, 2021.  The stock options were granted as induceme...

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress -- Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval -- -- XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020 -- -- Positive CHMP Opinion for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma Issued; European Commission Decision Expected by A...

Share this article Share this article NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval letter from the Israeli Ministry of Health, Israel's regulatory agency responsible for the approval of new medicines, granting the approval of XPOVIO® (selinexor) for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma (DLBCL). The approved in...